Rockville’s Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

Published on :

Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products [….]